Megaloensefali ile Giden Metabolik Hastalıklar
Özet
Megalensefali ile seyreden nörometabolik hastalıklar, klinik ve genetik açıdan heterojen, çocukluk çağında karşılaşılan karmaşık bir grubu oluşturur. Tanı süreci, detaylı klinik öykü, fizik muayene bulguları ve özellikle kranial MRI gibi görüntüleme yöntemlerinin yanı sıra, enzimatik ve genetik testlerin birlikte değerlendirilmesine dayanır. Bu hastalıkların erken teşhisi, progresif nörolojik hasarı engellemek veya destekleyici tedavilerle süreci yönetebilmek adına kritik bir öneme sahiptir. Etiyolojik sınıflandırma, altta yatan metabolik nedenlerin belirlenmesi ve uygun tedavi yaklaşımlarının geliştirilmesine yardımcı olmaktadır.
Neurometabolic disorders accompanied by megalencephaly represent a clinically and genetically heterogeneous group of complex conditions observed in pediatrics. The diagnostic process relies on a comprehensive assessment involving clinical history, physical examination, neuroimaging techniques such as cranial MRI, and specific enzymatic or genetic testing. Early diagnosis of these conditions is crucial for mitigating progressive neurological damage and implementing supportive therapeutic interventions. Etiological classification aids in identifying underlying metabolic causes, which is essential for establishing appropriate management and treatment strategies.
Referanslar
Jones KL, Smith’s Recognizable Patterns of Human Malformation, 6th edition. WB Saunders Company, Philadelphia 2006: 871-2.
Sandler AD, Knudsen MW, Brown TT et al. Neurodevelopmental dysfunctionamong nonreferred children with idiopathic megalencephaly. J Pediatr 1997; 131:320-4.
Sniderman A. Abnormal head growth. Pediatr Rev 2010;31:382–4. [1] Sniderman A. Abnormal head growth. Pediatr Rev 2010;31:382–4.
Liptak GS. Hydrocephalus. Pediatric Clinical Advisor – Instant diagnosis and treatment. 2nd edition, United States: Mosby Publications, 2007;281-2.
Hobbs C, Childs AM, Wynne J, et al. Subdural haematoma and effusion in infancy: an epidemiological study. Arch Dis Child 2005; 90:952.
Olney AH. Macrocephaly syndromes. Semin Pediatr Neurol 2007;14(3):128–135
Williams CA, Dagli A, Battaglia A. Genetic disorders associated with macrocephaly. AmJ Med Genet A 2008;146A(15):2023–2037
Leukoencephalopathies Associated with Macrocephaly Deborah L. Renaud, M.D. Semin Neurol 2012;32:34–41
Williams CA, Dagli A, Battaglia A. Genetic disorders associated with macrocephaly. AmJMed Genet A 2008;146A(15):2023–2037
Phealan JA Lowe LH Glaiser Cm. Pediatric neurodegenerative White matter process: leukodystrophies and beyond. Pediatr Radiol 2008;38:729-749.
Schiidelgrundes im gesunden und krankhaften Zustiinde und aber den Einfluss derselben aUf Schiidelform, Gesichtsbidung und Gehirnbau. Berlin: Georg Reimer, 1857:89-128.
Fletcher HM. A case of megalencephaly. Trans Pathol Soc (London) ,1900;51 :230-2.
Wilson KAS. Megalencephaly. J Neurol Psychopathol 1934;14: 193-216.
Norman RM. Megalencephaly. Greenfield's neuropathology. London: Arnold, 1963: 350
DeMyer W. Megalencephaly: types, clinical syndromes, and management. Pediatr Neurol 1986; 2:321.
Winden KD, Yuskaitis CJ, Poduri A.Megalencephaly andmacrocephaly. Semin Neurol 2015;35:277–87.
Mirzaa GM, Poduri A. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology. Am J Med Genet C Semin Med Genet 2014;166C:156–72.
A clinical review on megalencephaly A large brain as a possible sign of cerebral impairment Pavone et al. Medicine (2017) 96:26
Kaul R, Gao GP, Balamurugan K, Matalon R. Canavn Disease: Molecular basis of aspartoacylase deficiency. J Inherit Metab Dis 1994; 17:295.
Elpeleg ON, Anikster Y, Barash V, et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jewsin Israel. Am J Hum Genet 1994; 55-287.
Aspartoacylase gene in Canavan disease in non-Jewishpatients. Am J Hum Fenet 1995; 57:572.4
Michals K, Matalon R. Canavan disease. In: Raymond G, Eichler F, Fatemi A, Naidu S, eds. Leukodystrophies. London: Mac Keith Press; 2011;156–169
Surendran S, Michals-Matalon K, Quast MJ, et al. Canavan disease: a monogenic trait with complex genomic interaction. Mol Genet Metab 2003;80(1-2):74–80
Matalon R, Michals-Matalon K. Biochemistry and molecular biology of Canavan disease. Neurochem Res 1999;24(4):507–513
Steven JM, Curtis A, Given II. Case 99: Canavan Disease.Radiology 2006;241:310-24.
AL Baert, K Sartor, Massimo Filippi, Nicola de Stefano, Vincent Doussert. MR Imaging in white matter disease of the brain and spinal cord. Medical Radiology/Diagnostik İmaging. 2005.
Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases Barbara A Perez 1 et al. Brain Sci 2020 Feb 22;10(2):119.
Gordon N. Alexander disease. Eur J Paediatr Neurol. 2003;7:395--399.
Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Gold-man JE, Messing A. Mutations in GFAP, encoding glial fibrillaryacidic protein, are associated with Alexander disease. NatGenet. 2001;27:117---20.3.
Alexander WS.Progressive fibrinoid degeneration of fibrillary associated with mental retardation in a hydrocephalic infant. Brain 1949;72:373-381.
